Capricor Therapeutics

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Capricor Therapeutics reports strong Q4 performance and advances DMD therapy

Capricor Therapeutics showcased strong financial performance, progress in DMD therapy, and strategic partnerships with Nippon Shinyaku and NS Pharma.
The company faces challenges in FDA interactions, share sales, and potential acquisition decisions, but opportunities lie in market expansion and community engagement.
Overall, Capricor's confidence in its therapies and partnerships positions it well for future growth and impact in the Duchenne Muscular Dystrophy space.
The call concluded with gratitude towards participants, supporters, and the Capricor team, highlighting a positive outlook for the company's future endeavors.

Capricor Therapeutics advances DMD programs and secures Japan distribution

Capricor Therapeutics made significant progress in Q1 2023 with advancements in DMD programs, manufacturing, and clinical trials.
While facing financial losses, the company's strategic strengths include FDA discussions, partnerships, and international expansion.
Challenges in financial stability and operational efficiency need to be addressed, but opportunities in funding, market expansion, and innovation are promising.

Capricor Therapeutics reports Q2 progress with positive clinical outcomes

Capricor Therapeutics showcased solid financial performance amid ongoing R&D investments, with a focus on advancing innovative therapies for Duchenne muscular dystrophy.
The company's strengths lie in positive clinical trial outcomes, regulatory support, and strategic board additions, positioning Capricor for future growth and success.
Challenges include financial sustainability, trial coordination, and manufacturing scalability, which require careful management to navigate effectively.
Opportunities in new indications, partnerships, upcoming milestones, and technology advancement offer avenues for expansion, value creation, and competitive differentiation.

Capricor Therapeutics achieves enrollment goal, eyes FDA approval acceleration

Capricor Therapeutics is making significant strides in its clinical trials and manufacturing capabilities, supported by a strong financial position. While challenges exist in managing expenses and navigating regulatory processes, the company is well-positioned to capitalize on growth opportunities in the biopharmaceutical sector.

Capricor Therapeutics reports positive trial results and strategic partnerships for growth

Capricor Therapeutics' Q4 2023 performance reflects a strong financial position but with a net loss, driven by positive trial results for CAP-1002 in DMD.
The company's strengths include successful trial outcomes, strategic partnerships, and advancements in exosome technology development.
Challenges include operational losses, regulatory hurdles, and market competition, while opportunities exist in partnerships, FDA interactions, and technology development.
Overall, Capricor Therapeutics is poised for growth with a focus on commercialization, regulatory progress, and expanding therapeutic applications.

Capricor Therapeutics excels in Q1 2024, poised for market expansion

Capricor Therapeutics shows strong financial performance and progress in DMD trial, positioning CAP-1002 favorably in the market.
Strategic focus on regulatory alignment, commercial readiness, and potential expansions highlight growth opportunities.
Challenges in regulatory compliance, operational execution, and market competition require proactive management strategies.
Overall, Capricor's advancements in therapy development and market positioning indicate a promising outlook for future growth.

Capricor Therapeutics reports Q3 progress, eyes market expansion opportunities

Capricor Therapeutics demonstrated financial resilience with steady revenue growth and a strong cash position, despite a net loss.
The company's focus on product development, market expansion, and strategic collaborations underscores a commitment to innovation and growth.
While facing challenges in managing expenses and navigating regulatory complexities, Capricor is well-positioned to capitalize on opportunities in new therapeutic areas and market access.
Overall, Capricor's progress on deramiocel, manufacturing scale-up, and future development plans signal a promising trajectory for sustained growth and market success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. Linda Marbán, CEO of Capricor, will participate in a panel discussion at the virtual Cantor Fitzgerald Rare Orphan Disease Summit on March 30, 2022. Please see additional panel details below:

Capricor Therapeutics to Participate in the Cantor Fitzgerald Rare Orphan Disease Summit

Capricor Therapeutics Inc (NASDAQ: CAPR) announced topline data from its Phase 2 INSPIRE study evaluating a single-dose intravenous infusion of CAP-1002 for hospitalized COVID-19 patients. Capricor said that the trial met its primary objective of safety.

Capricor Shares Fall After Topline Results From Mid-Stage COVID-19 Trial

-Primary Objective of Study Met: CAP-1002 was Safe and Well Tolerated-

Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory INSPIRE Trial in Severe Hospitalized COVID-19 Patients

-One-Year Final Data Highlights Lead Cell Therapy Asset, CAP-1002, for Safety and Efficacy in Slowing Upper Limb and Cardiac Function Deterioration in Patients-

The Lancet Publishes Positive Results from Capricor Therapeutics' Phase 2 Study Evaluating CAP-1002 in Late-Stage Duchenne Muscular Dystrophy

Capricor Therapeutics, Inc. (CAPR) CEO Linda Marban on Q4 2021 Results - Earnings Call Transcript

Capricor Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Company to Host Conference Call, March 10, 2022, at 4:30 p.m. ET Company to Host Conference Call, March 10, 2022, at 4:30 p.m. ET

Capricor Therapeutics to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on March 10

Dr. Paulson Will Lead Clinical Efforts Focused on Capricor's Late-Stage Cell Therapy Program and its Expanding Exosome Platform-- Dr. Paulson Will Lead Clinical Efforts Focused on Capricor's Late-Stage Cell Therapy Program and its Expanding Exosome Platform--

Capricor Therapeutics Names Dr. Daniel Paulson as Vice President of Clinical Development

KYOTO, Japan, Jan. 25, 2022 /PRNewswire/ -- *NS Pharma Note: CAP-1002 is an investigational therapy and not approved in the US. This press release is being provided for a US audience as a reference.

Nippon Shinyaku and Capricor Therapeutics Enter into an Exclusive Partnership for Commercialization and Distribution of CAP-1002 for the Treatment* of Duchenne Muscular Dystrophy in US

Capricor Therapeutics Inc (NASDAQ: CAPR) has partnered with Nippon Shinyaku Co Ltd for the exclusive commercialization and distribution in the U.S of Capricor's CAP-1002 for Duchenne muscular dystrophy (DMD). Capricor's proprietary cell therapy, CAP-1002, comprises human allogeneic cardiosphere-derived cells.

Capricor Therapeutics, Nippon Shinyaku Ink US Pact For Duchenne Muscular Dystrophy Candidate

-Partnership Leverages Nippon Shinyaku's Deep Experience in Drug Development for Rare Diseases and its Commercial DMD Franchise in the U.S.-

Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in the U.S.

ENDRA Life Sciences

Boston Beer Company

Sirius XM Holdings Inc

Sunopta

Forget undervalued stocks, there is room for upside even in stocks with rising P/E.

Forget Bargains, Play 5 Stocks With Rising P/E Instead

Capricor's Exosome-based mRNA Vaccine for SARS-CoV-2 -In-Vivo Preclinical Data Published in the Journal of Biological Chemistry - -Preclinical Data Demonstrates Strong T-Cell Response for High Conserved N Protein which may Confer Longer Lasting Immunity- -Completing Non-Clinical Studies for IND Submission-

Capricor Therapeutics Announces Key Updates on its Vaccine and Therapeutic Programs for COVID-19

Capricor (CAPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Here's Why Capricor (CAPR) is Poised for a Turnaround After Losing 19.3% in 4 Weeks

– The Global, Virtual Event in Partnership with Genetic Engineering News (GEN) and the CRISPR Journal, Taking Place on November 16, 2021 – – The Global, Virtual Event in Partnership with Genetic Engineering News (GEN) and the CRISPR Journal, Taking Place on November 16, 2021 –

Capricor's CEO Dr. Linda Marbán to Serve as Keynote Speaker at TriLink Annual mRNA Day

Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q3 2021 Results - Earnings Call Transcript

Capricor (CAPR) delivered earnings and revenue surprises of 22.73% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Capricor Therapeutics (CAPR) Reports Q3 Loss, Lags Revenue Estimates

CAP-1002 – Capricor's Cell Therapy Program for Duchenne Muscular Dystrophy -Phase 3 Pivotal Study Cleared to Proceed- -Presented Positive Phase 2 HOPE-2 Data at Late-Breaking Oral Presentation at the  World Muscle Society Annual Meeting- -Met Primary Efficacy Endpoint of Mid Performance of Upper Limb (PUL) v1.2 (p=0.01)-

Capricor Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Company to Host Conference Call, November 9, 2021, at 4:30 p.m. ET Company to Host Conference Call, November 9, 2021, at 4:30 p.m. ET

Capricor Therapeutics to Present Third Quarter 2021 Financial Results and Recent Corporate Update on November 9

Capricor Therapeutics Inc (NASDAQ: CAPR) has announced final data from Phase 2 HOPE-2 trial of CAP-1002 for advanced stages of Duchenne muscular dystrophy (DMD).  The trial met its primary efficacy endpoint of mid-level performance of upper limb (mid-PUL v1.2) and various skeletal and cardiac function endpoints.

Capricor Stock Is Moving Higher As Duchenne Dystrophy Cell Therapy Slows Disease Progression By 71%

The stock price of Capricor Therapeutics Inc (NASDAQ: CAPR) increased by over 17% pre-market. This is why it happened.

CAPR Stock: Why It Substantially Increased Today

–Trial Met its Primary Efficacy Endpoint of Mid-level Performance of Upper Limb (PUL) v1.2 (p=0.01)–

Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002

-  Cantor Fitzgerald Virtual Global Healthcare Conference: September 30 -

Capricor Therapeutics to Present at the Upcoming Investor and Industry Healthcare Conferences

Aprea Therapeutics

ConforMIS

Spectrum Pharma

Verastem

Penny stocks with important dates to know this week. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 5 To Watch This Week With Biotech Catalysts

-Conference Dates: September 13–15, 2021- -Conference Dates: September 13–15, 2021-

News for Capricor Therapeutics Stock (CAPR)